Predicting glioblastoma response to bevacizumab through marker profiling?
Bevacizumab is a humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF). It has been approved for antiangiogenic treatment
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[2016]
|
| In: |
Neuro-Oncology
Year: 2016, Volume: 18, Issue: 2, Pages: 149-150 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/nov320 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/nov320 Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/neuro-oncology/article/18/2/149/2509286 
|
| Author Notes: | Tobias Kessler (Neurology Clinic, University Hospital Heidelberg and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany) |
| Summary: | Bevacizumab is a humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF). It has been approved for antiangiogenic treatment |
|---|---|
| Item Description: | Gesehen am 11.05.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/nov320 |